Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
ID: 343381Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is offering Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) to foster interdisciplinary collaborations aimed at addressing critical biomedical challenges. This funding opportunity encourages the integration of life and physical sciences through multidisciplinary bioengineering approaches to develop innovative technologies and methods in biomedical research, including design-directed and hypothesis-driven studies. The initiative is significant for advancing bioengineering solutions in healthcare, ultimately enhancing patient outcomes through scientific collaboration. Interested applicants, including higher education institutions, nonprofits, and local governments, must submit their proposals by September 7, 2025, and can find more information at NIH Grants. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    Files
    Title
    Posted
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces the Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) program aimed at fostering interdisciplinary collaborations to solve critical biomedical issues. Specifically, the grants encourage multidisciplinary bioengineering approaches that integrate physical and life sciences to develop innovative technologies and methods in biomedical research. Applications may propose diverse research types including design-directed and hypothesis-driven studies. Notably, the FOA will support clinical trials that validate tools or interventions with a focus on translational research, but not traditional phase III clinical trials. The funding opportunity is open to a variety of eligible organizations, including higher education institutions, nonprofits, and local governments, among others. Key submission dates and detailed application instructions are provided, emphasizing adherence to compliance requirements and registrations. The review process evaluates the significance, innovation, approach, and qualifications of the investigators, with an overall impact score reflecting the project's potential influence in the field. This initiative exemplifies NIH’s commitment to advancing bioengineering solutions in healthcare, enhancing patient outcomes through innovative scientific collaboration.
    Similar Opportunities
    Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Bioengineering Research Grants (BRG), aimed at fostering multidisciplinary collaborations to address significant biomedical challenges. This funding opportunity encourages innovative research that integrates life and physical sciences to develop tools, methods, and technologies that can enhance healthcare delivery and medical practices. Eligible applicants include a diverse range of institutions, such as historically black colleges, tribal colleges, and community-based organizations, with projects allowed to span up to five years under the R01 grant mechanism. Interested parties should submit their applications electronically by September 7, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding through the Exploratory/Developmental Bioengineering Research Grants (EBRG) program, aimed at enhancing biomedical research and clinical care. This initiative encourages innovative applications that focus on developing new capabilities to address challenges in biomedical, preclinical, or clinical settings, with an emphasis on feasibility testing and novel methodologies. The program is particularly significant for advancing cancer research through innovative bioengineering approaches, welcoming proposals from a diverse range of eligible applicants, including universities, nonprofits, and small businesses, especially those representing underrepresented groups. The maximum budget for applicants is $275,000 over two years, with applications due by January 7, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-321.html.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Bioengineering Research Grants (EBRG) under the R21 mechanism, aimed at fostering innovative engineering solutions to advance biomedical research. This funding opportunity encourages applications from a diverse range of organizations, including higher education institutions and nonprofits, to support exploratory projects that demonstrate feasibility and potential utility in addressing critical challenges in biomedical research and clinical care delivery, without involving clinical trials. The initiative emphasizes collaboration between quantitative and physical scientists and biomedical researchers, aiming to facilitate early-stage developments that can lead to significant advancements in medical technologies and methods. The funding ceiling is set at $275,000 over two years, with applications due by January 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-090.html.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed), aimed at advancing innovative bioengineering solutions to address cancer and other biomedical challenges. This funding opportunity encourages projects that demonstrate the feasibility and potential utility of novel capabilities to enhance biomedical research, clinical care delivery, and accessibility, while specifically discouraging clinical trial proposals. Eligible applicants include a diverse range of institutions such as higher education entities, nonprofits, for-profit organizations, and foreign entities, with a funding cap of $275,000 available over a two-year period. Interested applicants can find more information and submission guidelines on the NIH website, with applications due by January 7, 2028. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Exploratory/Developmental Bioengineering Research Grants (EBRG) under the R21 funding mechanism, aimed at fostering innovative projects that address significant biomedical challenges. This funding opportunity encourages applications that explore new capabilities or improvements in biomedical research, clinical care delivery, and accessibility, with a focus on groundbreaking engineering research and collaboration across diverse scientific disciplines. Eligible applicants include higher education institutions, nonprofits, and small businesses, with a budget cap of $275,000 over two years, and applications are due by January 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-091.html.
    Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)" aimed at fostering collaborative research partnerships between academic and industrial investigators to accelerate the development of innovative bioengineering tools and technologies. The program seeks to establish multidisciplinary teams that apply a quantitative bioengineering approach to address significant biomedical challenges, with a focus on creating robust solutions that can enhance life science understanding and medical practices within a 5-10 year timeframe. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and for-profit entities, particularly those emphasizing diversity in research. Interested parties should note that the application deadline is September 7, 2027, and for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information page at https://grants.nih.gov/grants/guide/pa-files/PAR-24-325.html.
    Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)" aimed at fostering collaborative research between academic institutions and industrial partners to accelerate the development of innovative bioengineering tools addressing critical biomedical challenges. This initiative seeks multidisciplinary teams that integrate engineering principles to create robust solutions capable of enhancing life sciences understanding and medical practices within a 5-10 year timeframe. The program emphasizes the importance of partnerships in overcoming development barriers and facilitating technology validation and commercialization, ultimately aiming to improve patient health outcomes. Interested applicants can find more details and submit inquiries via the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with applications due by January 7, 2025.
    Team-Based Design in Biomedical Engineering Education (R25 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Team-Based Design in Biomedical Engineering Education (R25 Clinical Trial Not Allowed)" aimed at enhancing biomedical engineering education through innovative team-based design courses. This initiative seeks to support educational programs that prepare undergraduate students in biomedical engineering/bioengineering fields to meet national biomedical needs, with a focus on promoting health equity and universal design. Institutions can apply for grants of up to $40,000 per year for projects lasting up to five years, with a submission deadline of January 30, 2025. Interested applicants should ensure compliance with eligibility criteria and submit detailed proposals that include innovative educational plans and collaborations with relevant disciplines; for further inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Building Biomedical Engineering Education, Research, and Innovation at Historically Black Colleges and Universities (HBCU eBETA) (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Building Biomedical Engineering Education, Research, and Innovation at Historically Black Colleges and Universities (HBCU eBETA)," aimed at enhancing research capacity and technology innovation in biomedical engineering at HBCUs. This initiative seeks to bolster education and career development in biomedical engineering, with a phased funding approach allowing for up to $300,000 in direct costs for planning (UG3 Phase) and potentially up to $1,000,000 for full-scale program implementation (UH3 Phase). The program emphasizes the importance of diversity in the scientific workforce and aims to address health disparities through improved training and partnerships. Interested applicants must submit their proposals by September 30, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/rfa-files/RFA-EB-25-002.html.
    Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)." This initiative aims to support the development of innovative biomimetic tissue-engineered technologies that accurately mimic cancer pathophysiology, facilitating advancements in cancer research and improving diagnostic and treatment strategies. The program encourages collaborative, multidisciplinary projects that integrate regenerative medicine, biomaterials, and bioengineering to create experimental models for studying cancer dynamics. Eligible applicants include a wide range of institutions and organizations, with funding of up to $400,000 in direct costs annually for projects lasting up to five years. Applications are due by May 7, 2025, and interested parties can contact NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-171.html.